Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection

Peptides

Volumn 28, Issue 3, 2007, Pages 496-504

  Devadas, Krishnakumar ^a   Boykins, Robert A ^a   Hewlett, Indira K ^a   Wood, Owen L ^a   Clouse, Kathleen A ^b   Yamada, Kenneth M ^c   Dhawan, Subhash ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Center for Drug Evaluation and Research   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

AIDS; HIV Tat; Peptides; Vaccination

Indexed keywords

AMINO ACID; ANTIBODY; ARGININE; CYSTEINE; EPITOPE; TRANSACTIVATOR PROTEIN;

ANTIBODY SPECIFICITY; ARTICLE; CHEMICAL MODIFICATION; CONJUGATION; CYTOPATHOGENIC EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREACTIVITY; MONOCYTE; PATHOGENESIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; VIRUS REPLICATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; EPITOPES; FEMALE; GENE PRODUCTS, TAT; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; VACCINES, CONJUGATE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 33846796058     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.11.007     Document Type: Article

References (42)

1. Agwale S.M., Shata M.T., Reitz M.S., Kalyanaraman V.S., Gallo R.C., Popovic M., et al. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice. Proc Natl Acad Sci 99 (2002) 10037-10041
2. Albini A., Barillari G., Benelli R., Gallo R.C., and Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci 92 (1995) 4838-4842
3. Albini A., Benelli R., Giunciuglio D., Cai T., Mariani G., Ferrini S., et al. Identification of a novel domain of HIV Tat involved in monocyte chemotaxis. J Biol Chem 273 (1998) 15895-15900
4. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
5. Badou A., Bennasser Y., Moreau M., Leclerc C., Benkirane M., and Bahraoui E. Tat protein of human immunodeficiency virus type1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol 74 (2000) 10551-10562
6. Belliard G., Hurtrel B., Moreau E., Lafont B.A.P., Monceaux V., Roques B.C., et al. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides. Vaccine 23 (2005) 1399-1407
7. Bohan C.A., Kashanchi F., Ensoli B., Buonaguro L., Boris-Lawrie K., and Brady J.N. Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr 2 (1992) 391-407
8. Boykins R.A., Mahieux R., Shankavaram U.T., Gho Y.S., Lee S.F., Hewlett I.K., et al. Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis. J Immunol 163 (1999) 15-20
9. Boykins R.A., Ardans J.A., Wahl L.M., Lal R.B., Yamada K.M., and Dhawan S. Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice. Peptides 21 (2000) 1839-1847
10. Boykins R.A., Joshi M., Syin C., Dhawan S., and Nakhasi H. Synthesis and construction of a novel multiple peptide conjugate system: strategy for a subunit vaccine design. Peptides 21 (2000) 9-17
11. Buonaguro L., Barillari G., Chang H.K., Bohan C.A., Kao V., Morgan R., et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 66 (1992) 7159-7167
12. Demarchi F., d'Adda di Fagagna F., Falaschi A., and Giacca M. Activation of transcription factor NF-kappa B by the Tat protein of human immunodeficiency virus type 1. J Virol 70 (1996) 4427-4437
13. Devadas K., and Dhawan S. Human immunodeficiency virus type-1 (HIV-1) Tat protein: mechanisms for activation of host factors and viral pathogenesis. Recent Res Devel Biochem 4 (2003) 447-466
14. Devadas K., Boykins R.A., Hardegen N.J., Philp D., Kleinman H.K., Osa E., et al. Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides. Peptides 27 (2006) 611-621
15. Dhawan S., Heredia A., Wahl L.M., Epstein J.S., Meltzer M.S., and Hewlett I.K. Interferon-gamma-induced downregulation of CD4 inhibits the entry of human immunodeficiency virus type-1 in primary monocytes. Pathobiology 63 (1995) 93-99
16. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67 (1993) 277-287
17. Fanales-Belasio E., Carafo A., Cara A., Negri D.R., Fiorelli V., Butto S., et al. HIV-1 Tat-based vaccines: from basic science to clinical trials. DNA Cell Biol 21 (2002) 599-610
18. Huang L., Bosch I., Hofmann W., Sodoroski J., and Pardee A.B. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol 72 (1998) 8952
19. Izmailova E., Bertley F.M.N., Huang Q., Makori N., Miller C.J., Young R.A., et al. HIV-1 Tat reprograms immature dendritic cells to express chemoacttractants for activated T cells and macrophages. Nat Med 9 (2003) 191
20. Kumar A., Manna S.K., Dhawan S., and Aggarwal B.B. HIV-Tat protein activates c-Jun N-terminal kinases and activator protein-1. J Immunol 161 (1998) 776
21. Lafrenie R.M., Wahl L.M., Epstein J.S., Hewlett I.K., Yamada K.M., and Dhawan S. HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes. J Immunol 157 (1996) 974
22. Lafrenie R.M., Wahl L.M., Epstein J.S., Yamada K.M., and Dhawan S. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 159 (1997) 4077
23. Mitola S., Soldi R., Zanon I., Barra L., Gutierrez M.I., Berkhout B., et al. Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells. J Virol 74 (2000) 344
24. Moreau E., Belliard G., Partidos C.D., Pradezinsky F., Le Buanec H., Muller S., et al. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides. J Gen Virol 85 (2004) 2893
25. Moreau E., Hoebeke J., Zagury D., Muller S., and Desgranges C. Generation and characterization of neutralizing human monoclonal antibodies against Human Immunodeficiency Virus type 1 Tat antigen. J Virol 78 (2004) 3792
26. Nath A., Conant K., Chen P., Scott C., and Major E.O. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. J Biol Chem 274 (1999) 17098
27. Noonan D.M., Gingeri A., Meazza R., Rosso O., Mazza S., Muca-Perja M.H., et al. Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers. J Acqir Immune Defic Syndr 33 (2003) 47
28. Ott M., Lovett J.L., Mueller L., and Verdin E. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-κB factors. J Immunol 160 (1998) 2872
29. Partidos C.D., Moreau E., Chaloin O., Tunis M., Briand J.P., Desgranges C., et al. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity. Eur J Immunol 34 (2004) 3723-3731
30. Pauza C.D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W., et al. Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci 97 (2000) 3515-3519
31. Ramakrishna L., Anand K.K., Mohankumar K.M., and Ranga U. Codon optimization of the Tat antigen of human immunodeficiency virus type-1 generates strong immune responses in mice following genetic immunization. J Virol 78 (2004) 9174-9189
32. Ranga U., Shankarappa R., Siddappa N., Ramakrishna L., Nagendran R., Mahalingam M., et al. Tat protein of Human Immunodeficiency Virus type 1 subtype C strains is a defective chemokine. J Virol (2004) 2586-2590
33. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Zauli G., and La Placa M. Antibody against human deficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. Clin Diagn Lab Immunol 3 (1996) 230-232
34. Rezza G., Fiorelli V., Dorrucci M., Ciccozzi M., Tripiciano A., Scoglio A., et al. The presence of anti-Tat antibodies is predictive of Long-term nonprogression to AIDS of severe immunodeficiency: fndings in a cohort of HIV-1 seroconverters. J Infect Dis 191 (2005) 1321-1324
35. Richardson M.W., Mirchandani J., Duong J., Grimaldo S., Kocieda V., Hendel H., et al. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 57 (2003) 4-14
36. Richardson M.W., Mirchandani J., Silvera P., Regulier E.G., Capini C., Bojczuk P.M., et al. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses. DNA Cell Biol 21 (2002) 637-651
37. Silvera P., Richardson M.W., Greenhouse J., Yalley-Ogunro J., Shaw N., Mirchandani J., et al. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus. J Virol 76 (2002) 3800-3809
38. Tikhonov I., Ruckwardt T.J., Hatfield G.S., and Pauza C.D. Tat-neutralizing antibodies in vaccinated macaques. J Virol 77 (2003) 3157-3166
39. Van Baalen C.A., Pontesilli O., Huisman A.M., Klein M.R., de Wolf F., Miedema F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 78 (1997) 1913-1918
40. Wahl L.M., Katona I.M., Wilder R.L., Winter C.C., Haraoui B., Scher I., et al. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis. Cell Immunol 85 (1984) 373-383
41. Weiss J.M., Nath A., Major E.O., and Berman J.W. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol 163 (1999) 2953-2959
42. Yedavalli V.S., Benkirane M., and Jeang K.T. Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem 278 (2003) 6404-6410